Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Suicide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    362 result(s) found for: Suicide. Displaying page 2 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-000271-39 Sponsor Protocol Number: 2022-01 Start Date*: 2022-09-02
    Sponsor Name:Adeptio Pharmaceuticals Ltd
    Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004327-13 Sponsor Protocol Number: H8Y-MC-HBBV Start Date*: 2012-02-06
    Sponsor Name:Eli Lilly and Company
    Full Title: Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) BE (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002788-88 Sponsor Protocol Number: 20190529 Start Date*: 2021-01-11
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Yea...
    Medical condition: Juvenile psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021143-41 Sponsor Protocol Number: 31-10-270 Start Date*: 2010-12-22
    Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc.
    Full Title: An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) BG (Completed) SK (Completed) HU (Completed) EE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005388-32 Sponsor Protocol Number: ACP-103-070 Start Date*: 2022-07-05
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD)
    Medical condition: Irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005292-17 Sponsor Protocol Number: TRx-237-008 Start Date*: 2012-10-02
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of LMTM in Subjects with Mild to Moderate Alzheimer’s Disease on Pre-Existing Stable Acetylcholinesterase Inhibi...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004378-27 Sponsor Protocol Number: CAFQ056A2299 Start Date*: 2012-03-30
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson?s patients with L-dopa induced dyskinesias
    Medical condition: L-dopa induced dyskinesias in patients with Parkinson?s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10013929 Dyskinesias and movement disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Completed) DE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004334-42 Sponsor Protocol Number: 31-08-252 Start Date*: 2013-02-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder
    Medical condition: Bipolar I disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-001619-65 Sponsor Protocol Number: TV46000-CNS-30072 Start Date*: 2018-11-14
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneou...
    Medical condition: Maintenance treatment of schizophrenia in patients currently treated with oral antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001131-23 Sponsor Protocol Number: S015-002 Start Date*: 2011-09-21
    Sponsor Name:Siena Biotech SpA
    Full Title: A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003039-31 Sponsor Protocol Number: D1002002 Start Date*: 2015-08-20
    Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd.
    Full Title: A Long-Term Study of SM-13496 in Patients with Bipolar I Disorder
    Medical condition: Bipolar I depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001041-15 Sponsor Protocol Number: N3D/FOR-OCA-06 Start Date*: 2004-07-26
    Sponsor Name:Neuro3d
    Full Title: MULTICENTRE, DOUBLE-BLIND, RISING DOSE PARALLEL GROUP STUDY OF THE EFFICACY AND TOLERABILITY OF OCAPERIDONE VERSUS OLANZAPINE IN SCHIZOPHRENIC PATIENTS
    Medical condition: The populations of the study will be: -schizophrenic patients according to DSM IV-TR diagnosis -have to present the first symptoms of the schizophrenia for at least one year -have to present an exa...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000213-19 Sponsor Protocol Number: 99824 Start Date*: 2005-03-08
    Sponsor Name:Lundbeck SA
    Full Title: Sertindole versus risperidone safety outcome study: A randomised, partially-blinded, parallel-group, active-controlled, post-marketing study
    Medical condition: Schizophrenic patients most recently treated with antipsychotics other than sertindole or risperidone, requiring a new prescription for an antipsychotic, and without any contraindications for eithe...
    Disease: Version SOC Term Classification Code Term Level
    7 10037175 Psyc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-006914-41 Sponsor Protocol Number: CBASP-1 Start Date*: 2008-09-29
    Sponsor Name:Dept. of Psychiaty, University of Freiburg
    Full Title: Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma
    Medical condition: Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus Escitalopram in chronic major depression with and without early trauma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003587-34 Sponsor Protocol Number: IPR/01 Start Date*: 2007-04-12
    Sponsor Name:MolMed
    Full Title: A phase I-II study: infusion of donor lymphocytes transduced with the suicide gene HSV TK, after transplantation of allogeneic T-depleted stem cells from a haploidentical donor in patients with hae...
    Medical condition: Hematological malignancies at high risk of relapse based on disease progression or presence of negative prognostic factor, who have received a HCTfrom donor HLA mismatched (haploidentical) for 2 o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002386-18 Sponsor Protocol Number: 11-185/CAIAC Start Date*: 2016-03-15
    Sponsor Name:RWTH Aachen Clinical Trials Center Aachen (CTC-A)
    Full Title: Network connectivity and inhibitory control under atomoxetin challenge - A pharamacological "resting state" and "inhibitory task" fMRI study in patients with ADHD
    Medical condition: Patients with Attention-Deficit/Hyperactivity Disorders (ADHD)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000282-20 Sponsor Protocol Number: EBS-101-OL-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Emalex Biosciences, Inc.
    Full Title: A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome
    Medical condition: Children and Adolescent Subjects with Tourette’s Syndrome greater than or equal to 6 and less than or equal to 18 years of age
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000688-22 Sponsor Protocol Number: 750203.01.002 Start Date*: 2020-10-16
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-centre, double-blind, placebo- and reference-controlled, randomised trial to prove the efficacy and safety of Silexan (WS®1265) in patients with a major depressive episode of mild to moderate...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10083288 Clinical depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000243-27 Sponsor Protocol Number: BUPROPION2019 Start Date*: 2019-03-18
    Sponsor Name:Odense University Hospital
    Full Title: The effect of bupropion in peripheral neuropathic pain. A randomized, double-blind, placebo-controlled study.
    Medical condition: Peripheral neuropathic , i.e. painful polyneuropathy, postherpetic neuralgia and pain after nerve injury (traumatic or surgical).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10077974 Peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001348-25 Sponsor Protocol Number: COMP004 Start Date*: 2020-07-08
    Sponsor Name:COMPASS Pathways, Ltd
    Full Title: A multicentre study to assess safety and efficacy of psilocybin in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU)
    Medical condition: Treatment-Resistant Depression (P-TRD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) CZ (Completed) DK (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 17:29:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA